This week, the tweet of the week comes from Paul DeSantis, who questions whether Carl Icahn might get involved with Gilead Sciences (NASDAQ:GILD) considering all the cash the biotech is expected to throw off over the next few years.
In the video below, senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss why Icahn might want to become an activist investor in Gilead Sciences and whether that should scare investors. Considering his track record of getting companies sold -- MedImmune to AstraZeneca (NYSE:AZN), Genzyme to Sanofi, ImClone Systems to Eli Lilly (NYSE:LLY), just to name a few -- it can be an advantage to have Icahn on your side in the short term.
In the long run, it's an entirely different story.
Brian Orelli has no position in any stocks mentioned. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Berkshire Hathaway and Gilead Sciences. The Motley Fool owns shares of Berkshire Hathaway. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.
Which stock wins in a head-to-head match-up between the big biotech and the big pharma company?
Is Gilead Sciences, Inc. a Buy in 2018?
Focus on the future rather than the past for this big biotech.
2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better
In the short term, the biotech's success is still tied to its HIV and HCV franchises, but keep an eye on the pipeline.